Dexcom | DXCM - Cash And Equivalent


Dexcom reported $917.7M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Abbott USD 8.52B 1.01B Dec/2025
Align Technology USD 1B 103.43M Sep/2025
AtriCure USD 167.43M 19.56M Dec/2025
Avanos Medical USD 89.8M 19.3M Dec/2025
Baxter International USD 1.97B 240M Dec/2025
Becton, Dickinson and Co. USD 740M 99M Dec/2025
Boston Scientific USD 1.96B 690M Dec/2025
Cooper Companies USD 124.9M 13.3M Jun/2025
Dexcom USD 917.7M 918M Dec/2025
Edwards Lifesciences USD 2.69B 587.2M Sep/2025
Globus Medical USD 526.16M 154.39M Dec/2025
Hologic USD 2.17B 208.5M Dec/2025
Inogen USD 106.48M 2.79M Sep/2025
Insulet USD 716.1M 41.3M Dec/2025
Integra LifeSciences USD 232.19M 14.27M Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Masimo USD 312.3M 162.7M Sep/2025
Medtronic USD 1.28B 9M Sep/2025
Merit Medical Systems USD 446.4M 53.95M Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Solventum Corp USD 1.64B 1.15B Sep/2025
Stryker USD 4.01B 755M Dec/2025
Tandem Diabetes Care USD 90.63M 1.31M Dec/2025
Teleflex USD 354M 100.3M Sep/2025
West Pharmaceutical Services USD 791.3M 162.8M Dec/2025
Zimmer Biomet Holdings USD 591.9M 700.8M Dec/2025